TY - JOUR
T1 - The Differential Clinical Impacts of Cachexia and Sarcopenia on the Prognosis of Advanced Pancreatic Cancer
AU - Hou, Ya Chin
AU - Chen, Chien Yu
AU - Huang, Chien Jui
AU - Wang, Chih Jung
AU - Chao, Ying Jui
AU - Chiang, Nai Jung
AU - Wang, Hao Chen
AU - Tung, Hui Ling
AU - Liu, Hsiao Chun
AU - Shan, Yan Shen
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Pancreatic cancer (PC) has the highest frequency of developing cancer cachexia (CC)– sarcopenia (SC) syndrome, which negatively influences patients’ outcome, quality of life, and toler-ance/response to treatments. However, the clinical impacts of CC, SC, and their associated factors on outcomes for advanced PC has yet to be fully investigated. A total of 232 patients were enrolled in this study for the retrospective review of their clinical information and the measurement of skeletal muscle areas at the third lumber vertebra by computed tomography scan to identify CC or SC. The association and concurrent occurrence of clinicopathological features in each patient, prevalence rates, and prognosis with the CC or SC were calculated. CC and SC were observed in 83.6% (n = 194) and 49.1% (n = 114) of PC patients, respectively. Low hemoglobin levels more often occurred in CC patients than in non-CC patients (p = 0.014). Older age (p = 0.000), female gender (p = 0.024), low body mass index (BMI) values (p = 0.004), low hemoglobin levels (p = 0.036), and low albumin levels (p = 0.001) were more often found in SC patients than in non-SC patients. Univariate and multivariate analyses showed that CC was an independent poor prognostic factor of overall survival (OS) and progression-free survival for all patients, the chemotherapy (C/T) subgroup, and the high BMI subgroup. Meanwhile, SC was an independent predictor of poor OS for the subgroups of C/T or high BMI but not for all patients. These findings reveal the clinical differences for CC and SC and provide useful information for predicting the prognosis of advanced PC patients and conducting personalized medicine.
AB - Pancreatic cancer (PC) has the highest frequency of developing cancer cachexia (CC)– sarcopenia (SC) syndrome, which negatively influences patients’ outcome, quality of life, and toler-ance/response to treatments. However, the clinical impacts of CC, SC, and their associated factors on outcomes for advanced PC has yet to be fully investigated. A total of 232 patients were enrolled in this study for the retrospective review of their clinical information and the measurement of skeletal muscle areas at the third lumber vertebra by computed tomography scan to identify CC or SC. The association and concurrent occurrence of clinicopathological features in each patient, prevalence rates, and prognosis with the CC or SC were calculated. CC and SC were observed in 83.6% (n = 194) and 49.1% (n = 114) of PC patients, respectively. Low hemoglobin levels more often occurred in CC patients than in non-CC patients (p = 0.014). Older age (p = 0.000), female gender (p = 0.024), low body mass index (BMI) values (p = 0.004), low hemoglobin levels (p = 0.036), and low albumin levels (p = 0.001) were more often found in SC patients than in non-SC patients. Univariate and multivariate analyses showed that CC was an independent poor prognostic factor of overall survival (OS) and progression-free survival for all patients, the chemotherapy (C/T) subgroup, and the high BMI subgroup. Meanwhile, SC was an independent predictor of poor OS for the subgroups of C/T or high BMI but not for all patients. These findings reveal the clinical differences for CC and SC and provide useful information for predicting the prognosis of advanced PC patients and conducting personalized medicine.
UR - http://www.scopus.com/inward/record.url?scp=85132799328&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132799328&partnerID=8YFLogxK
U2 - 10.3390/cancers14133137
DO - 10.3390/cancers14133137
M3 - Article
AN - SCOPUS:85132799328
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 13
M1 - 3137
ER -